Company intelligence / Profile preview

Juvenomics

Douglas, Isle of Man

Ownership: Private
Development stage: Other

Overview

Juvenomics is a longevity-focused biotechnology company formed as a joint venture between Juvenescence and G3 Therapeutics. The company was established to apply deep molecular profiling, large-scale biological data, and deep learning to discover and develop medicines targeting aging and age-related disease. Publicly available information indicates that Juvenomics is oriented around an AI-enabled discovery platform rather than a disclosed clinical pipeline of named drug candidates. Based on the available sources, the company appears to be a private, health-focused biotech operating in the emerging longevity and computational drug discovery space.

Therapeutic areas: Other
Industry: Biotech

Partnerships

JuvenescenceG3 Therapeutics

Beyond the preview

Go deeper on Juvenomics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Juvenomics.

Explore the full profile